Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
Jaclyn Flanigan, Hari Deshpande, Scott GettingerYale Cancer Center/Yale University School of Medicine New Haven, CT, USAAbstract: Vandetanib (ZD6474) is an oral small molecule inhibitor of multiple intracellular receptor kinases, including the vascular endothelial growth factor receptor (VEGFR) -2 a...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2010-08-01
|
| Series: | Biologics: Targets & Therapy |
| Online Access: | http://www.dovepress.com/current-status-of-vandetanib-zd6474-in-the-treatment-of-non-small-cell-a5138 |